Clinical Trial Update: Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP [Phase 4]

View source ↗

Summary

A Phase 4 trial update investigates using reduced-dose dasatinib (70 mg daily) as first-line treatment for newly diagnosed chronic myeloid leukemia in chronic p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Shenzhen Second People's Hospital | Conditions: Dasatinib, BCR-ABL | Phase 4 | Status: UNKNOWN